Literature DB >> 18797822

Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours.

P Castaldi1, V Rufini, G Treglia, I Bruno, G Perotti, G Stifano, B Barbaro, A Giordano.   

Abstract

PURPOSE: Somatostatin receptor scintigraphy with [(111)In]-diethylene triamine pentaacetate acid (DTPA)-octreotide is an accurate method for detecting neuroendocrine tumours (NETs) but often does not provide clear anatomical localisation of lesions. The aim of this study was to assess the clinical usefulness of anatomical-functional image fusion.
MATERIALS AND METHODS: Fifty-four patients with known or suspected NET were included in the study. Planar and single-photon-emission computed tomography (SPECT) imaging was performed using a dual-head gamma camera equipped with an integrated X-ray transmission system, and the images were first interpreted alone by two nuclear medicine physicians and then compared with SPECT/CT fusion images together with a radiologist. The improvement provided by SPECT/CT in the interpretation of SPECT data alone and any modification in patient management were recorded.
RESULTS: Fusion images improved SPECT interpretation in 23 cases, providing precise anatomical localisation of increased tracer uptake in 20 cases and disease exclusion in sites of physiological uptake in 5. In 10 patients, SPECT/CT allowed definition of the functional significance of lesions detected by diagnostic CT. SPECT/CT data modified clinical management in 14 cases by changing the diagnostic approach in 8 and the therapeutic modality in 6.
CONCLUSIONS: Our study demonstrates that image fusion is clearly superior to SPECT alone, allowing precise localisation of lesions and reducing false-positive results.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18797822     DOI: 10.1007/s11547-008-0319-9

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  28 in total

1.  The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms.

Authors:  E Even-Sapir; Z Keidar; J Sachs; A Engel; L Bettman; D Gaitini; L Guralnik; N Werbin; G Iosilevsky; O Israel
Journal:  J Nucl Med       Date:  2001-07       Impact factor: 10.057

Review 2.  The radionuclide molecular imaging and therapy of neuroendocrine tumors.

Authors:  Shuren Li; Mohsen Beheshti
Journal:  Curr Cancer Drug Targets       Date:  2005-03       Impact factor: 3.428

3.  Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours.

Authors:  Michael Gabriel; Florian Hausler; Reto Bale; Roy Moncayo; Clemens Decristoforo; Peter Kovacs; Irene Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-26       Impact factor: 9.236

4.  Classification and nomenclature of somatostatin receptors.

Authors:  D Hoyer; G I Bell; M Berelowitz; J Epelbaum; W Feniuk; P P Humphrey; A M O'Carroll; Y C Patel; A Schonbrunn; J E Taylor
Journal:  Trends Pharmacol Sci       Date:  1995-03       Impact factor: 14.819

Review 5.  Nuclear medicine imaging of neuroendocrine tumours.

Authors:  E Bombardieri; M Maccauro; E De Deckere; G Savelli; A Chiti
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

6.  Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma.

Authors:  K Tharp; O Israel; J Hausmann; L Bettman; W H Martin; M Daitzchman; M P Sandler; D Delbeke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-19       Impact factor: 9.236

Review 7.  [New perspectives in diagnosis and therapy of endocrine gastroenteropancreatic (GEP) tumors with somatostatin analogues].

Authors:  D Rubello; V Rufini; E De Carlo; C Martini; M L Calcagni; N Sicolo; L Troncone; D Casara
Journal:  Minerva Endocrinol       Date:  2003-12       Impact factor: 2.184

Review 8.  The diagnosis and medical management of advanced neuroendocrine tumors.

Authors:  Gregory A Kaltsas; G Michael Besser; Ashley B Grossman
Journal:  Endocr Rev       Date:  2004-06       Impact factor: 19.871

9.  Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.

Authors:  A Chiti; S Fanti; G Savelli; A Romeo; B Bellanova; M Rodari; B J van Graafeiland; N Monetti; E Bombardieri
Journal:  Eur J Nucl Med       Date:  1998-10

10.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

Authors:  I Buchmann; M Henze; S Engelbrecht; M Eisenhut; A Runz; M Schäfer; T Schilling; S Haufe; T Herrmann; U Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-23       Impact factor: 9.236

View more
  12 in total

Review 1.  SPECT/CT and tumour imaging.

Authors:  Gad Abikhzer; Zohar Keidar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-29       Impact factor: 9.236

Review 2.  Molecular imaging agents for SPECT (and SPECT/CT).

Authors:  Gopinath Gnanasegaran; James R Ballinger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-07       Impact factor: 9.236

3.  Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography.

Authors:  Ka-Kit Wong; Arpit Gandhi; Benjamin L Viglianti; Lorraine M Fig; Domenico Rubello; Milton D Gross
Journal:  World J Radiol       Date:  2016-06-28

Review 4.  Imaging of neuroendocrine gastroenteropancreatic tumours.

Authors:  R Graziani; A Brandalise; M Bellotti; R Manfredi; A Contro; M Falconi; L Boninsegna; R Pozzi Mucelli
Journal:  Radiol Med       Date:  2010-03-09       Impact factor: 3.469

5.  Automatic and manual image fusion of In-pentetreotide SPECT and diagnostic CT in neuroendocrine tumor imaging - An evaluation.

Authors:  Elisabeth Hedlund; Jan-Erik Karlsson; Sven-Åke Starck
Journal:  J Med Phys       Date:  2010-10

6.  Bone metastasis from a neuroendocrine tumor detected by 99m-technetium-hydrazinonicotinyl-Tyr3-octreotide single-photon emission computed tomography/computed tomography.

Authors:  Koramadai Karuppusamy Kamaleshwaran; Paul Vannan Subramanian; Sudhakar Natarajan; Vyshak Mohanan; Ajit Sugunan Shinto
Journal:  Indian J Nucl Med       Date:  2013-07

7.  Splenosis Mimicking Relapse of a Neuroendocrine Tumor at Gallium-68-DOTATOC PET/CT.

Authors:  Giorgio Treglia; Luca Giovanella; Barbara Muoio; Carmelo Caldarella
Journal:  Nucl Med Mol Imaging       Date:  2013-11-26

8.  A novel statistical analysis method to improve the detection of hepatic foci of (111)In-octreotide in SPECT/CT imaging.

Authors:  Tobias Magnander; E Wikberg; J Svensson; P Gjertsson; B Wängberg; M Båth; Peter Bernhardt
Journal:  EJNMMI Phys       Date:  2016-01-19

Review 9.  Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development.

Authors:  Rocio Garcia-Carbonero; Roberto Garcia-Figueiras; Alberto Carmona-Bayonas; Isabel Sevilla; Alex Teule; Maria Quindos; Enrique Grande; Jaume Capdevila; Javier Aller; Javier Arbizu; Paula Jimenez-Fonseca
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

10.  Improved Benefit of SPECT/CT Compared to SPECT Alone for the Accurate Localization of Endocrine and Neuroendocrine Tumors.

Authors:  Gonca G Bural; Ashok Muthukrishnan; Matthew J Oborski; James M Mountz
Journal:  Mol Imaging Radionucl Ther       Date:  2012-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.